Incyte (INCY) is set to receive a $25M milestone payment from Novartis (NVS) as a Phase II...

|About: Incyte Corporation (INCY)|By:, SA News Editor

Incyte (INCY) is set to receive a $25M milestone payment from Novartis (NVS) as a Phase II clinical trial for INC280 formally gets underway. NVS has exclusive development and commercialization rights to the compound. (PR)